In a remarkable results, CRSP shows that their gene editing treatment, using the CRISPR-Cas9 technology that recently won its co-founder Emmanuelle Charpentier the 2020 Nobel Prize in chemistry, effectively cured one patient of sickle cell anemia and another of B-thalassemia. CRSP announces these results in a talk at the American Society of Hematologists and in a publication in the premier medical journal- NEJM
https://www.nejm.org/doi/full/10.1056/NEJMoa2031054?query=featured_home
This is the first time gene editing has cured a genetic disease in patients.
CRSP and the other gene editing stocks EDIT, NTLA, and BEAM have had great runs this year, and their technology has now been validated in a landmark study.
Submitted December 05, 2020 at 10:53PM by Social_History https://ift.tt/37Dtpcj
